Study of TGM-312-SC01 in Healthy Participants and Adults With MASH

计划入组 99 人 · 首次发布于 2026 年 2 月 23 日

Study of UB-312 in Healthy Participants and Parkinson's Disease Patients

计划入组 70 人 · 首次发布于 2019 年 8 月 30 日

UB-312 in Patients With Synucleinopathies

计划入组 8 人 · 首次发布于 2022 年 12 月 2 日

TGM-004

TGM-002

TGM-001

Oystershell NV

Belgium

Izana Bioscience Ltd.

United Kingdom

Biotechnology General (Israel) Ltd.

Israel

Tangram Therapeutics Initiates First-in-Human Trial of TGM-312 for MASH Treatment

Tangram Therapeutics Advances Novel RNAi Therapy TGM-312 to Clinical Trials for MASH Treatment

Tangram's TGM-312 Advances to MASH Patient Cohorts in Phase 1/2 RESTORE-MASH Trial